48-year-old with Altered Mental Status and Respiratory Failure: A Case Report

Justin E. Pile, DO, MS* Justina Truong, DO[†] *Swedish Hospital, Northshore University HealthSystem, Department of Emergency Medicine, Chicago, Illinois *Kingman Regional Medical Center, Department of Emergency Medicine, Kingman, Arizona

Section Editor: John Ashurst, DO

Submission history: Submitted December 27, 2020; Revision received March 4, 2021; Accepted March 8, 2021 Electronically published April 23, 2021 Full text available through open access at http://escholarship.org/uc/uciem_cpcem DOI: 10.5811/cpcem.2021.3.51331

Introduction: The differential diagnosis for altered mental status and respiratory failure is broad. Careful physical examination, appropriate use of diagnostic tools, and accurate interpretation and correlation of test results are important for piecing together the puzzle of a patient with altered mental status that emergency physicians commonly face. In certain cases, such as this one, rapid diagnosis and management is crucial for improving patient morbidity and mortality.

Case Presentation: A 48-year-old male with altered mental status and respiratory failure presented to the emergency department after being found unconscious on his porch. Vital signs were notable for temperature 105.5 °F, blood pressure 202/102 millimeters of mercury, pulse 126 beats per minute, respiratory rate 30 breaths per minute, and oxygen saturation 91% on room air. Physical examination revealed an obese male lying in bed awake in severe distress with labored breathing and unable to converse. His physical examination was significant for dry mucous membranes, tachycardia, and bilateral lower extremity 1+ pitting edema. He also appeared to have Kussmaul respirations with severe tachypnea, but his breath sounds were clear to auscultation bilaterally. On further examination, the patient appeared to have intravenous (IV) injection markings along his arms suggesting the possibility of IV drug use.

Discussion: With limited history, the only context clues initially available to assist in the diagnosis were abnormal vital signs and physical examination. The patient was tachycardic, hyperthermic, hypertensive, hypoxic, and tachypneic with altered mental status; he eventually required endotracheal intubation for hypoxic respiratory failure. The complexity of his condition prompted a large list for the differential diagnoses. Toxidromes, endocrine abnormalities, infectious process, cardiac and/or renal etiologies, and neurological pathology such as a cerebrovascular accident were considered. In the case of this patient, urgent diagnosis and management was crucial to prevent further decompensation and improve his outcome. [Clin Pract Cases Emerg Med. 2021;5(4):502–506.]

Keywords: Cardiorenal Syndrome, Respiratory Failure, Altered Mental Status, Sepsis, Case Report.

CASE PRESENTATION (Resident Presentation)

A 48-year-old male presented to the emergency department (ED) via ambulance after being found unconscious on his porch. The paramedics stated the patient had labored breathing and altered mental status but did answer a few questions appropriately. The patient denied any drug use, but emergency medical services had administered eight milligrams of naloxone to him prior to arrival to the ED. In the ED, additional history including a review of systems was limited secondary to the patient's clinical condition.

Vital signs were as follows: temperature 105.5 degrees Fahrenheit (°F), blood pressure 202/102 millimeters of mercury, pulse 126 beats per minute, respiratory rate 30 breaths per minute, and oxygen saturation 91% on room air. Physical examination revealed an obese male lying in bed awake in severe distress with labored breathing and unable to converse. Due to patient distress, orientation could not be assessed. He was able to move all extremities and had no facial asymmetry, but a full neurological exam was limited secondary to clinical condition. His physical examination was significant for dry mucous membranes, tachycardia, and bilateral lower extremity 1+ pitting edema. He also appeared to have Kussmaul respirations with severe tachypnea but had breath sounds clear to auscultation bilaterally. On further examination, the patient appeared to have intravenous (IV) injection markings along his arms suggesting the possibility of IV drug use.

Laboratory and imaging evaluation in the ED included numerous diagnostic tests. Abnormal laboratory results were found within the complete blood count, comprehensive metabolic panel, lactic acid, lactate dehydrogenase, creatine kinase, C-reactive protein, procalcitonin, high-sensitivity troponin, B-type natriuretic peptide, D-dimer, international normalized ratio, fibrinogen, urinalysis, urine culture, blood cultures, arterial blood gas, and urine drug screen. An electrocardiogram (ECG), chest radiograph (CXR), computed tomography (CT) of the head without contrast, and CT of the chest, abdomen, and pelvis with contrast were ordered.

Unfortunately, the patient's mental and respiratory status did not improve while in the ED and he was intubated and mechanically ventilated due to hypoxic respiratory failure. He was started on a propofol infusion for post-intubation sedation, which assisted in blood pressure reduction. Given his hyperthermia at 105.5°F, passive cooling was initiated, and judicious fluid administration was considered in light of possible congestive heart failure. Thus, a one-liter normal saline bolus was administered. Broad spectrum antibiotics including vancomycin and piperacillin/tazobactam were initiated as well. The patient was admitted to the intensive care unit (ICU).

CASE DISCUSSION (Attending Discussion)

Based on the limited information, the differential diagnosis inferred from the patient's presentation remained broad. The top considerations were infection, toxidrome, endocrine abnormality, or metabolic emergency. Based on the laboratory and imaging results presented below in Table 1 and Images 1 and 2, certain diagnoses were considered more or less likely. For example, due to the patient's tachycardia, hyperthermia, and altered mental status, thyroid storm was considered in the differential diagnosis. No thyroid studies were ordered as there were other more likely causes of the patient's presentation. Another endocrine abnormality considered was diabetic ketoacidosis, but this was less likely considering a blood glucose level in the high 100s, negative ketones in the urine, as well as a pH that was slightly alkaline. Examination showed no signs of major trauma or focal neurological deficits. Imaging of
 Table 1. Laboratory values of a 48-year-old male with respiratory distress and altered mental status.

Laboratory nameLaboratory valueReference rangesComplete Blood Count	distress and altered mental status.		
Complete Blood Count White blood cell16.354.50-11 mL 13.7Hemoglobin13.713.5-18 g/dLHematocrit43.940.0-54.0%Platelet count194130-500 K/mLNeutrophil percentage88.140.0-74.0%Lymphocyte percentage4.819.0-48.0%Comprehensive Metabolic PanelSodium131Sodium131135-147 3.4-Potassium4.05.3 mEq/LChloride9696-108 mEq/LCarbon dioxide2122-32 mEq/LAnion gap140-16Glucose186< 133		Laboratory	Reference
White blood cell16.354.50-11 mLHemoglobin13.713.5-18 g/dLHematocrit43.940.0-54.0%Platelet count194130-500 K/mLNeutrophil percentage88.140.0-74.0%Lymphocyte percentage4.819.0-48.0%Comprehensive Metabolic Panel5.3 mEq/LSodium131135-147 3.4-Potassium4.05.3 mEq/LChloride9696-108 mEq/LCarbon dioxide2122-32 mEq/LAnion gap140-16Glucose186< 133	Laboratory name	value	ranges
White blood cell16.354.50-11 mLHemoglobin13.713.5-18 g/dLHematocrit43.940.0-54.0%Platelet count194130-500 K/mLNeutrophil percentage88.140.0-74.0%Lymphocyte percentage4.819.0-48.0%Comprehensive Metabolic Panel5.3 mEq/LSodium131135-147 3.4-Potassium4.05.3 mEq/LChloride9696-108 mEq/LCarbon dioxide2122-32 mEq/LAnion gap140-16Glucose186< 133	Complete Blood Count		
$\begin{array}{llllllllllllllllllllllllllllllllllll$		16.35	4.50-11 mL
$\begin{array}{c c c c c c c c c c c c c c c c c c c $			
Platelet count194130-500 K/mLNeutrophil percentage88.140.0-74.0%Lymphocyte percentage4.819.0-48.0%Comprehensive Metabolic Panel131135-147 3.4-Potassium4.05.3 mEq/LChloride9696-108 mEq/LCarbon dioxide2122-32 mEq/LAnion gap140-16Glucose186< 133			-
Neutrophil percentage88.140.0-74.0%Lymphocyte percentage4.819.0-48.0%Comprehensive Metabolic Panel50Sodium131135-147 3.4-Potassium4.05.3 mEq/LChloride9696-108 mEq/LCarbon dioxide2122-32 mEq/LAnion gap140-16Glucose186<133			
$\begin{tabular}{ c c c c c c c } Lymphocyte percentage & 4.8 & 19.0-48.0\% \\ \hline Comprehensive Metabolic Panel & & & & & & & & & & & & & & & & & & &$			
$\begin{array}{c c c c c c c c c c c c c c c c c c c $			
$\begin{array}{cccc} \text{Sodium} & 131 & 135-147 \ 3.4-\\ \text{Potassium} & 4.0 & 5.3 \ \text{mEq/L} \\ \text{Chloride} & 96 & 96-108 \ \text{mEq/L} \\ \text{Carbon dioxide} & 21 & 22-32 \ \text{mEq/L} \\ \text{Anion gap} & 14 & 0-16 \\ \text{Glucose} & 186 & <133 \\ \text{Blood urea nitrogen} & 43 & 7-23 \ \text{mg/dL} \\ \text{Creatinine} & 2.2 & 0.4-1.3 \ \text{mg/dL} \\ \text{Estimated glomerular} & 38.9 & \geq 60 \\ \text{filtration rate (Black/African} \\ \text{American} \\ \text{American} \\ \text{Blood urea nitrogen/} & 19 & 7-28 \ \text{Ratio} \\ \text{Creatinine ratio} \\ \text{Calcium} & 9.1 & 8.6-10.5 \ \text{mg/dL} \\ \text{Total Bilirubin} & 8.7 & 0.2-1.4 \ \text{mg/dL} \\ \text{Aspartate aminotransferase} & 151 & 5-34 \ \text{U/L} \\ \text{Alanine aminotransferase} & 47 & 5-50 \ \text{U/L} \\ \text{Alkaline phosphatase} & 95 & 46-116 \ \text{U/L} \\ \text{Total protein} & 7.2 & 6.0-8.0 \ \text{g/dL} \\ \text{Albumin} & 3.8 & 3.5-5.0 \ \text{g/dL} \\ \text{Miscellaneous Labs} \\ \text{Lactic acid} & 2.6 & 0.5-2.2 \ \text{mmol/L} \\ \text{Procalcitonin} & 125.37 & <0.050 \ \text{ng/ml} \\ \text{High sensitivity troponin \#1} & 492.4 & 0-53.5 \ \text{ng/ml} \\ \text{High sensitivity troponin \#2} & 585.9 & 0-53.5 \ \text{ng/ml} \\ \text{High sensitivity troponin \#2} & 585.9 & 0-53.5 \ \text{ng/ml} \\ \text{Myoglobin} & >900 & <10-110 \ \text{ng/ml} \\ \text{Total creatine kinase} & 5913 & 46-171 \ \text{U/L} \\ \text{Lactate dehydrogenase} & 457 & 120-246 \ \text{U/L} \\ \text{Brain natriuretic peptide} & 1317.6 & 0-100.0 \ \text{pg/ml} \\ \text{C-reactive protein} & 185.9 & 0-10 \ \text{mg/L} \\ \text{International normalized ratio} & 1.4 & 0.8-1.2 \\ \text{Partial thromboplastin time} & 34.3 & 25.0-37.0 \ \text{sec} \\ \text{D-dimer} & 1.810 & <0.500 \ \text{mg/ml} \\ \text{Ethyl alcohol} & <10 & 0.10 \ \text{mg/dL} \\ \text{Salicylates} & <3.0 & 2.0-29.0 \ \text{mg/ml} \\ \text{Ethyl alcohol} & <10 & 0.109 \ \text{mg/ml} \\ \text{Ethyl alcohol} & <10 & 0.109 \ \text{mg/ml} \\ \text{Ethyl alcohol} & <10 & 0.109 \ \text{mg/ml} \\ \text{Ethyl alcohol} & <10 & 0.109 \ \text{mg/ml} \\ \text{Ethyl alcohol} & <10 & 0.109 \ \text{mg/ml} \\ \text{Ethyl alcohol} & <10 & 0.109 \ \text{mg/ml} \\ \text{Ethyl alcohol} & <10 & 0.109 \ \text{mg/ml} \\ \text{Ethyl alcohol} & <10 & 0.109 \ \text{mg/ml} \\ \text{Ethyl alcohol} & <10 & 0.109 \ \text{mg/ml} \\ \text{Ethyl alcohol} & <10 & 0.109 \ m$		1.0	10.0 10.070
$\begin{array}{cccc} \mbox{Potassium} & 4.0 & 5.3 \mbox{ mEq/L} \\ \mbox{Chloride} & 96 & 96-108 \mbox{ mEq/L} \\ \mbox{Carbon dioxide} & 21 & 22-32 \mbox{ mEq/L} \\ \mbox{Carbon dioxide} & 21 & 22-32 \mbox{ mEq/L} \\ \mbox{Anion gap} & 14 & 0-16 \\ \mbox{Glucose} & 186 & <133 \\ \mbox{Blood urea nitrogen} & 43 & 7-23 \mbox{ mg/dL} \\ \mbox{Creatinine} & 2.2 & 0.4-1.3 \mbox{ mg/dL} \\ \mbox{Estimated glomerular} & 38.9 & \geq 60 \\ \mbox{filtration rate (Black/African} & & & & & & & & & & & & & & & & & & &$		101	405 447 0 4
$\begin{array}{cccc} \mbox{Chloride} & 96 & 96-108\ mEq/L \\ \mbox{Carbon dioxide} & 21 & 22-32\ mEq/L \\ \mbox{Anion gap} & 14 & 0-16 \\ \mbox{Glucose} & 186 & <133 \\ \mbox{Blood urea nitrogen} & 43 & 7-23\ mg/dL \\ \mbox{Creatinine} & 2.2 & 0.4-1.3\ mg/dL \\ \mbox{Creatinine ratio} & 2.2 & 0.4-1.3\ mg/dL \\ \mbox{Estimated glomerular} & 38.9 & \geq 60 \\ \mbox{filtration rate (Black/African} & & & & & & \\ \mbox{American} & & & & & & \\ \mbox{Blood urea nitrogen} & 19 & 7-28\ \mbox{Ratio} & & & & \\ \mbox{Creatinine ratio} & & & & & & \\ \mbox{Creatinine ratio} & & & & & & \\ \mbox{Calcium} & 9.1 & 8.6-10.5\ \mbox{mg/dL} \\ \mbox{Aspartate aminotransferase} & 151 & 5-34\ \mbox{U/L} \\ \mbox{Alanine aminotransferase} & 151 & 5-34\ \mbox{U/L} \\ \mbox{Alamine phosphatase} & 95 & 46-116\ \mbox{U/L} \\ \mbox{Albumin} & 3.8 & 3.5-5.0\ \mbox{g/dL} \\ \mbox{Albumin} & 125.37 & <0.050\ \mbox{ng/ml} \\ \mbox{High sensitivity troponin \#1} \\ \mbox{High sensitivity troponin \#2} \\ \mbox{Myoglobin} & & & & & & & & \\ \mbox{Procalcitonin} & 125.37 & 120-246\ \mbox{U/L} \\ \mbox{Brain natriuretic peptide} & 1317.6 & 0-100.0\ \mbox{ng/ml} \\ \mbox{High sensitivity troponin #2} \\ \mbox{Partial thromboplastin time} & 34.3 & 250-37.0\ \mbox{sec} \\ \mbox{Partial thromboplastin time} & 34.3 & 250-37.0\ \mbox{sec} \\ \mbox{Partial thromboplastin time} & 34.3 & 250-37.0\ \mbox{sec} \\ \mbox{Partial thromboplastin time} & 34.3 & 250-37.0\ \mbox{sec} \\ \mbox{Partial thromboplastin time} & 1.810 & <0.500\ \mbox{ng/ml} \\ \mbox{Fibrinogen} & 604 & 175-400\ \mbox{mg/dL} \\ \mbox{Salicylates} & <3.0 & 2.0-29.0\ \mbox{mg/dL} \\ \mbox{Acetaminophen} & 4 & 0-199\ \mbox{mg/ml} \\ \mbox{Ethyl alcohol} & <10 & 0-10\ \mbox{mg/dL} \\ \mbox{Acetaminophen} & 4 & 0-199\ \mbox{mg/ml} \\ \mbox{Acteaminophen} & 4 &$			
$\begin{array}{ccc} {\rm Carbon dioxide} & 21 & 22-32 \mbox{ mcg/L} \\ {\rm Anion gap} & 14 & 0-16 \\ {\rm Glucose} & 186 & <133 \\ {\rm Blood urea nitrogen} & 43 & 7-23 \mbox{ mg/dL} \\ {\rm Creatinine} & 2.2 & 0.4-1.3 \mbox{ mg/dL} \\ {\rm Estimated glomerular} & 38.9 & \geq 60 \\ {\rm filtration rate (Black/African American)} \\ {\rm Blood urea nitrogen/} & 19 & 7-28 \mbox{ Ratio} \\ {\rm Creatinine ratio} & & & & & & \\ {\rm Creatinine ratio} & & & & & & \\ {\rm Calcium} & 9.1 & 8.6-10.5 \mbox{ mg/dL} \\ {\rm Aspartate aminotransferase} & 151 & 5-34 \mbox{ U/L} \\ {\rm Alganine aminotransferase} & 151 & 5-34 \mbox{ U/L} \\ {\rm Alganine aminotransferase} & 47 & 5-50 \mbox{ U/L} \\ {\rm Alkaline phosphatase} & 95 & 46-116 \mbox{ U/L} \\ {\rm Albumin} & 3.8 & 3.5-5.0 \mbox{ g/dL} \\ {\rm Albumin} & 3.8 & 3.5-5.0 \mbox{ g/dL} \\ {\rm Miscellaneous Labs} & & & & & \\ {\rm Lactic acid} & 2.6 & 0.5-2.2 \mbox{ mmol/L} \\ {\rm Procalcitonin} & 125.37 & <0.050 \mbox{ ng/ml} \\ {\rm High sensitivity troponin \#1} & 492.4 & 0-53.5 \mbox{ ng/ml} \\ {\rm High sensitivity troponin \#2} & 585.9 & 0-53.5 \mbox{ ng/ml} \\ {\rm High sensitivity troponin \#2} & 5913 & 46-171 \mbox{ U/L} \\ {\rm Lactate dehydrogenase} & 457 & 120-246 \mbox{ U/L} \\ {\rm Brain natriuretic peptide} & 1317.6 & 0-100.0 \mbox{ ng/ml} \\ {\rm C-reactive protein} & 185.9 & 0-10 \mbox{ mg/l} \\ {\rm International normalized ratio} & 1.4 & 0.8-1.2 \\ {\rm Partial thromboplastin time} & 34.3 & 250-37.0 \mbox{ sec} \\ {\rm Partial thromboplastin time} & 34.3 & 250-37.0 \mbox{ sec} \\ {\rm D-dimer} & 1.810 & <0.500 \mbox{ mg/ml} \\ {\rm Fibrinogen} & 604 & 175-400 \mbox{ mg/ml} \\ {\rm Kotup Lacton} & <3.0 & 2.0-29.0 \mbox{ mg/ml} \\ {\rm Kotup Lacton} & <3.0 & 2.0-29.0 \mbox{ mg/ml} \\ {\rm Ethyl alcohol} & <10 & 0-10 \mbox{ mg/ml} \\ {\rm Kotup Lacton} & <3.0 & 2.0-29.0 \mbox{ mg/ml} \\ {\rm Ethyl alcohol} & <10 & 0-10 \mbox{ mg/ml} \\ {\rm Moto Detected} \\ {\rm negative} & \\ {\rm Moto Detected} \\ {\rm negative} & \\ {\rm Moto Detected} \\ {\rm negative} & \\ {\rm Motom} & <1.5 \mbox{ mg/ml} \\ {\rm CoVID-19 \ PCR} & $2.5 \ 3.5.0-45.0 \ \\ {\rm Motom} & \\ {\rm Motom} & \\ {\rm Actaminophen} & 4 & 0-199 $			
Anion gap140-16Glucose186< 133	-		
$\begin{array}{cccc} {\rm Glucose} & 186 & < 133 \\ {\rm Blood urea nitrogen} & 43 & 7-23 {\rm mg/dL} \\ {\rm Creatinine} & 2.2 & 0.4-1.3 {\rm mg/dL} \\ {\rm Estimated glomerular} & 38.9 & \geq 60 \\ {\rm filtration rate (Black/African \\ {\rm American}) & \\ {\rm Blood urea nitrogen/} & 19 & 7-28 {\rm Ratio} \\ {\rm Creatinine ratio} & \\ {\rm Calcium} & 9.1 & 8.6-10.5 {\rm mg/dL} \\ {\rm Aspartate aminotransferase} & 151 & 5-34 U/L \\ {\rm Alanine aminotransferase} & 47 & 5-50 U/L \\ {\rm Alkaline phosphatase} & 95 & 46-116 U/L \\ {\rm Total protein} & 7.2 & 6.0-8.0 {\rm g/dL} \\ {\rm Albumin} & 3.8 & 3.5-5.0 {\rm g/dL} \\ \\ {\rm Miscellaneous Labs} & \\ {\rm Lactic acid} & 2.6 & 0.5-2.2 {\rm mmol/L} \\ {\rm Procalcitonin} & 125.37 & < 0.050 {\rm ng/ml} \\ {\rm High sensitivity troponin \#1} & 492.4 & 0-53.5 {\rm ng/ml} \\ {\rm High sensitivity troponin \#2} & 585.9 & 0-53.5 {\rm ng/ml} \\ {\rm Myoglobin} & >900 & < 10-110 {\rm ng/ml} \\ {\rm Total creatine kinase} & 5913 & 46-171 U/L \\ {\rm Lactate dehydrogenase} & 457 & 120-246 U/L \\ {\rm Brain natriuretic peptide} & 1317.6 & 0-100.0 {\rm pg/ml} \\ {\rm International normalized ratio} & 1.4 & 0.8-1.2 \\ {\rm Partial thromboplastin time} & 34.3 & 25.0-37.0 {\rm sec} \\ {\rm D-dimer} & 1.810 & < 0.500 {\rm mg/ml} \\ {\rm Fibrinogen} & 604 & 175-400 {\rm mg/dL} \\ {\rm Salicylates} & < 3.0 & 2.0-29.0 {\rm mg/dL} \\ {\rm Acetaminophen} & 4 & 0.199 {\rm mg/ml} \\ {\rm Ethyl alcohol} & < 10 & 0-10 {\rm mg/dL} \\ {\rm CoVID-19 \ PCR} & {\rm Presumptive} \\ {\rm negative} & \\ {\rm Arterial Blood Gas} \\ {\rm pH} & 7.49 & 7.35-7.45 {\rm pH} \\ {\rm pCO}_2 & 27.5 & 35.0-45.0 \\ \end{array} \right$	-		
Blood urea nitrogen437-23 mg/dLCreatinine2.20.4-1.3 mg/dLEstimated glomerular38.9≥ 60filtration rate (Black/African American)197-28 RatioBlood urea nitrogen/197-28 RatioCreatinine ratio0197-28 RatioCalcium9.18.6-10.5 mg/dL8.6-10.5 mg/dLAspartate aminotransferase1515-34 U/LAlanine aminotransferase475-50 U/LAlkaline phosphatase9546-116 U/LTotal protein7.26.0-8.0 g/dLAlbumin3.83.5-5.0 g/dLMiscellaneous Labs2.60.5-2.2 mmol/LLactic acid2.60.5-2.2 mmol/LProcalcitonin125.37<0.050 ng/ml			
Creatinine2.20.4-1.3 mg/dLEstimated glomerular38.9≥ 60filtration rate (Black/African38.9≥ 60American)Blood urea nitrogen/197-28 RatioCreatinine ratio0197-28 RatioCalcium9.18.6-10.5 mg/dLTotal Bilirubin8.70.2-1.4 mg/dLAspartate aminotransferase1515-34 U/LAlanine aminotransferase475-50 U/LAlkaline phosphatase9546-116 U/LTotal protein7.26.0-8.0 g/dLAlbumin3.83.5-5.0 g/dLMiscellaneous Labs2.60.5-2.2 mmol/LLactic acid2.60.5-2.2 mmol/LProcalcitonin125.37<0.050 ng/ml	Glucose	186	
Estimated glomerular filtration rate (Black/African American)38.9≥ 60Blood urea nitrogen/ Creatinine ratio Calcium197-28 RatioTotal Bilirubin8.70.2-1.4 mg/dLAspartate aminotransferase1515-34 U/LAlanine aminotransferase475-50 U/LAlkaline phosphatase9546-116 U/LTotal protein7.26.0-8.0 g/dLAlbumin3.83.5-5.0 g/dLMiscellaneous Labs2.60.5-2.2 mmol/LLactic acid2.60.5-2.2 mmol/LProcalcitonin125.37<0.050 ng/ml	Blood urea nitrogen	43	7-23 mg/dL
filtration rate (Black/African American)Blood urea nitrogen/ Creatinine ratio197-28 RatioCalcium9.18.6-10.5 mg/dLTotal Bilirubin8.70.2-1.4 mg/dLAspartate aminotransferase1515-34 U/LAlanine aminotransferase475-50 U/LAlkaline phosphatase9546-116 U/LTotal protein7.26.0-8.0 g/dLAlbumin3.83.5-5.0 g/dLMiscellaneous Labs2.60.5-2.2 mmol/LLactic acid2.60.5-2.2 mmol/LProcalcitonin125.37<0.050 ng/ml	Creatinine	2.2	0.4-1.3 mg/dL
American) Blood urea nitrogen/ Creatinine ratio Calcium197-28 RatioCalcium9.18.6-10.5 mg/dLTotal Bilirubin8.70.2-1.4 mg/dLAspartate aminotransferase1515-34 U/LAlanine aminotransferase475-50 U/LAlkaline phosphatase9546-116 U/LTotal protein7.2 $6.0-8.0$ g/dLAlbumin3.8 $3.5-5.0$ g/dLMiscellaneous LabsLactic acid2.6 $0.5-2.2$ mmol/LProcalcitonin125.37<0.050 ng/ml	Estimated glomerular	38.9	≥ 60
American) Blood urea nitrogen/ Creatinine ratio Calcium197-28 RatioCalcium9.18.6-10.5 mg/dLTotal Bilirubin8.70.2-1.4 mg/dLAspartate aminotransferase1515-34 U/LAlanine aminotransferase475-50 U/LAlkaline phosphatase9546-116 U/LTotal protein7.2 $6.0-8.0$ g/dLAlbumin3.8 $3.5-5.0$ g/dLMiscellaneous LabsLactic acid2.6 $0.5-2.2$ mmol/LProcalcitonin125.37<0.050 ng/ml	filtration rate (Black/African		
$\begin{array}{c c} \mbox{Creatinine ratio} \\ \mbox{Calcium} & 9.1 & 8.6-10.5 \mbox{ mg/dL} \\ \mbox{Total Bilirubin} & 8.7 & 0.2-1.4 \mbox{ mg/dL} \\ \mbox{Aspartate aminotransferase} & 151 & 5-34 \mbox{U/L} \\ \mbox{Alanine aminotransferase} & 47 & 5-50 \mbox{U/L} \\ \mbox{Alkaline phosphatase} & 95 & 46-116 \mbox{U/L} \\ \mbox{Total protein} & 7.2 & 6.0-8.0 \mbox{g/dL} \\ \mbox{Albumin} & 3.8 & 3.5-5.0 \mbox{g/dL} \\ \mbox{Albumin} & 3.8 & 3.5-5.0 \mbox{g/dL} \\ \mbox{Miscellaneous Labs} \\ \mbox{Lactic acid} & 2.6 & 0.5-2.2 \mbox{mmol/L} \\ \mbox{Procalcitonin} & 125.37 & <0.050 \mbox{ng/ml} \\ \mbox{High sensitivity troponin #1} & 492.4 & 0-53.5 \mbox{ng/ml} \\ \mbox{High sensitivity troponin #2} & 585.9 & 0-53.5 \mbox{ng/ml} \\ \mbox{High sensitivity troponin #2} & 585.9 & 0-53.5 \mbox{ng/ml} \\ \mbox{Myoglobin} & >900 & <10-110 \mbox{ng/ml} \\ \mbox{Total creatine kinase} & 5913 & 46-171 \mbox{U/L} \\ \mbox{Lactate dehydrogenase} & 457 & 120-246 \mbox{U/L} \\ \mbox{Brain natriuretic peptide} & 1317.6 & 0-100.0 \mbox{pg/ml} \\ \mbox{C-reactive protein} & 185.9 & 0-10 \mbox{mg/L} \\ \mbox{International normalized ratio} & 1.4 & 0.8-1.2 \\ \mbox{Partial thromboplastin time} & 34.3 & 25.0-37.0 \mbox{sec} \\ \mbox{D-dimer} & 1.810 & <0.500 \mbox{mg/ml} \\ \mbox{Fibrinogen} & 604 & 175-400 \mbox{mg/dL} \\ \mbox{Salicylates} & <3.0 & 2.0-29.0 \mbox{mg/ml} \\ \mbox{Ethyl alcohol} & <10 & 0-10 \mbox{mg/ml} \\ \mbox{Ethyl alcohol} & <10 & 0-10 \mbox{mg/ml} \\ \mbox{COVID-19 PCR} & \mbox{Presumptive} \\ \mbox{negative} & \nbox{Not Detected} \\ \mbox{PH} & 7.49 & 7.35-7.45 \mbox{ pH} \\ \mbox{pCO}_2 & 27.5 & 35.0-45.0 \\ \end{tabular}$			
$\begin{array}{c c} \mbox{Creatinine ratio} \\ \mbox{Calcium} & 9.1 & 8.6-10.5 \mbox{ mg/dL} \\ \mbox{Total Bilirubin} & 8.7 & 0.2-1.4 \mbox{ mg/dL} \\ \mbox{Aspartate aminotransferase} & 151 & 5-34 \mbox{U/L} \\ \mbox{Alanine aminotransferase} & 47 & 5-50 \mbox{U/L} \\ \mbox{Alkaline phosphatase} & 95 & 46-116 \mbox{U/L} \\ \mbox{Alkaline phosphatase} & 95 & 46-116 \mbox{U/L} \\ \mbox{Albumin} & 3.8 & 3.5-5.0 \mbox{g/dL} \\ \mbox{Albumin} & 125.37 & <0.050 \mbox{ng/ml} \\ \mbox{High sensitivity troponin #1} & 492.4 & 0-53.5 \mbox{ng/ml} \\ \mbox{High sensitivity troponin #1} & 492.4 & 0-53.5 \mbox{ng/ml} \\ \mbox{High sensitivity troponin #2} & 585.9 & 0-53.5 \mbox{ng/ml} \\ \mbox{High sensitivity troponin #2} & 585.9 & 0-53.5 \mbox{ng/ml} \\ \mbox{High sensitivity troponin #2} & 585.9 & 0-53.5 \mbox{ng/ml} \\ \mbox{Myoglobin} & >900 & <10-110 \mbox{ng/ml} \\ \mbox{Total creatine kinase} & 5913 & 46-171 \mbox{U/L} \\ \mbox{Lactate dehydrogenase} & 457 & 120-246 \mbox{U/L} \\ \mbox{Brain natriuretic peptide} & 1317.6 & 0-100.0 \mbox{pg/ml} \\ \mbox{C-reactive protein} & 185.9 & 0-10 \mbox{mg/L} \\ \mbox{International normalized ratio} & 1.4 & 0.8-1.2 \\ \mbox{Partial thromboplastin time} & 34.3 & 25.0-37.0 \mbox{ sec} \\ \mbox{D-dimer} & 1.810 & <0.500 \mbox{mg/ml} \\ \mbox{Fibrinogen} & 604 & 175-400 \mbox{mg/dL} \\ \mbox{Salicylates} & <3.0 & 2.0-29.0 \mbox{mg/ml} \\ \mbox{Ethyl alcohol} & <10 & 0-10 \mbox{mg/ml} \\ \mbox{Ethyl alcohol} & <10 & 0-10 \mbox{mg/ml} \\ \mbox{Not Detected} \\ \mbox{negative} \\ \mbox{Not Detected} \\ \mbox{negative} \\ \mbox{Arterial Blood Gas} \\ \mbox{pH} & 7.49 & 7.35-7.45 \mbox{pH} \\ \mbox{pCO}_2 & 27.5 & 35.0-45.0 \\ \mbox{Not Detected} \\ No$	Blood urea nitrogen/	19	7-28 Ratio
Total Bilirubin8.7 $0.2-1.4 \text{ mg/dL}$ Aspartate aminotransferase151 $5-34 \text{ U/L}$ Alanine aminotransferase47 $5-50 \text{ U/L}$ Alkaline phosphatase95 $46-116 \text{ U/L}$ Total protein7.2 $6.0-8.0 \text{ g/dL}$ Albumin3.8 $3.5-5.0 \text{ g/dL}$ Miscellaneous LabsLactic acid 2.6 Lactic acid 2.6 $0.5-2.2 \text{ mmol/L}$ Procalcitonin125.37 $<0.050 \text{ ng/ml}$ High sensitivity troponin #1492.4 $0-53.5 \text{ ng/ml}$ Myoglobin >900 $<10-110 \text{ ng/ml}$ Total creatine kinase 5913 $46-171 \text{ U/L}$ Lactate dehydrogenase 457 $120-246 \text{ U/L}$ Brain natriuretic peptide 1317.6 $0-100.0 \text{ pg/ml}$ C-reactive protein 185.9 $0-10 \text{ mg/L}$ International normalized ratio 1.4 $0.8-1.2$ Partial thromboplastin time 34.3 $25.0-37.0 \text{ sec}$ D-dimer 1.810 $<0.500 \text{ mg/ml}$ Fibrinogen 604 $175-400 \text{ mg/dL}$ Salicylates <3.0 $2.0-29.0 \text{ mg/dL}$ Acetaminophen 4 $0-199 \text{ mg/ml}$ Ethyl alcohol <10 $0-10 \text{ mg/dL}$ COVID-19 PCRPresumptive negativeNot Detected negativePH 7.49 $7.35-7.45 \text{ pH}$ pCO_2 27.5 $35.0-45.0$			
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Calcium	9.1	8.6-10.5 mg/dL
$\begin{array}{llllllllllllllllllllllllllllllllllll$	Total Bilirubin	8.7	
$\begin{array}{c cccc} \mbox{Alanine aminotransferase} & 47 & 5-50 \ U/L \\ \mbox{Alkaline phosphatase} & 95 & 46-116 \ U/L \\ \mbox{Total protein} & 7.2 & 6.0-8.0 \ g/dL \\ \mbox{Albumin} & 3.8 & 3.5-5.0 \ g/dL \\ \hline \mbox{Miscellaneous Labs} & & & & & & \\ \mbox{Lactic acid} & 2.6 & 0.5-2.2 \ mmol/L \\ \mbox{Procalcitonin} & 125.37 & <0.050 \ ng/ml \\ \mbox{High sensitivity troponin #1} & 492.4 & 0-53.5 \ ng/ml \\ \mbox{High sensitivity troponin #2} & 585.9 & 0-53.5 \ ng/ml \\ \mbox{Myoglobin} & >900 & <10-110 \ ng/ml \\ \mbox{Total creatine kinase} & 5913 & 46-171 \ U/L \\ \mbox{Lactate dehydrogenase} & 457 & 120-246 \ U/L \\ \mbox{Brain natriuretic peptide} & 1317.6 & 0-100.0 \ pg/ml \\ \mbox{C-reactive protein} & 185.9 & 0-10 \ mg/L \\ \mbox{International normalized ratio} & 1.4 & 0.8-1.2 \\ \mbox{Partial thromboplastin time} & 34.3 & 25.0-37.0 \ sec \\ \mbox{D-dimer} & 1.810 & <0.500 \ mg/ml \\ \mbox{Fibrinogen} & 604 & 175-400 \ mg/dL \\ \mbox{Salicylates} & <3.0 & 2.0-29.0 \ mg/dL \\ \mbox{Acetaminophen} & 4 & 0-199 \ mg/ml \\ \mbox{Ethyl alcohol} & <10 & 0-10 \ mg/dL \\ \mbox{COVID-19 PCR} & \mbox{Presumptive} \\ \mbox{Not Detected} \\ \mbox{pH} & 7.49 & 7.35-7.45 \ pH \\ \mbox{pCO}_2 & 27.5 & 35.0-45.0 \\ \end{tabular}$	Aspartate aminotransferase		
$\begin{array}{cccc} \mbox{Alkaline phosphatase} & 95 & 46-116 U/L \\ \mbox{Total protein} & 7.2 & 6.0-8.0 g/dL \\ \mbox{Albumin} & 3.8 & 3.5-5.0 g/dL \\ \end{array}$	•		
Total protein7.2 $6.0-8.0 \text{ g/dL}$ Albumin 3.8 $3.5-5.0 \text{ g/dL}$ Miscellaneous Labs 2.6 $0.5-2.2 \text{ mmol/L}$ Procalcitonin 125.37 $<0.050 \text{ ng/ml}$ High sensitivity troponin #1 492.4 $0-53.5 \text{ ng/ml}$ Myoglobin >900 $<10-110 \text{ ng/ml}$ Total creatine kinase 5913 $46-171 \text{ U/L}$ Lactate dehydrogenase 457 $120-246 \text{ U/L}$ Brain natriuretic peptide 1317.6 $0-100.0 \text{ pg/ml}$ C-reactive protein 185.9 $0-50 \text{ mg/L}$ International normalized ratio 1.4 $0.8-1.2$ Partial thromboplastin time 34.3 $25.0-37.0 \text{ sec}$ D-dimer 1.810 $<0.500 \text{ mg/ml}$ Fibrinogen 604 $175-400 \text{ mg/dL}$ Salicylates <3.0 $2.0-29.0 \text{ mg/dL}$ Acetaminophen 4 $0-199 \text{ mg/ml}$ Ethyl alcohol <10 $0-10 \text{ mg/dL}$ COVID-19 PCRPresumptive negativeNot DetectedPH pCO_2 7.49 $7.35-7.45 \text{ pH}$ pH pCO_2 27.5 $35.0-45.0$			
Albumin 3.8 $3.5-5.0 \text{ g/dL}$ Miscellaneous Labs2.6 $0.5-2.2 \text{ mmol/L}$ Procalcitonin 125.37 $<0.050 \text{ ng/ml}$ High sensitivity troponin #1 492.4 $0.53.5 \text{ ng/ml}$ High sensitivity troponin #2 585.9 $0.53.5 \text{ ng/ml}$ Myoglobin >900 $<10-110 \text{ ng/ml}$ Total creatine kinase 5913 $46-171 \text{ U/L}$ Lactate dehydrogenase 457 $120-246 \text{ U/L}$ Brain natriuretic peptide 1317.6 $0-100.0 \text{ pg/ml}$ C-reactive protein 185.9 $0-10 \text{ mg/L}$ International normalized ratio 1.4 $0.8-1.2$ Partial thromboplastin time 34.3 $25.0-37.0 \text{ sec}$ D-dimer 1.810 $<0.500 \text{ mg/ml}$ Fibrinogen 604 $175-400 \text{ mg/dL}$ Salicylates <3.0 $2.0-29.0 \text{ mg/dL}$ Acetaminophen 4 $0-199 \text{ mg/ml}$ Ethyl alcohol <10 $0-10 \text{ mg/dL}$ Not DetectednegativeNot Detected pH 7.49 $7.35-7.45 \text{ pH}$ pCO_2 27.5 $35.0-45.0$			
Miscellaneous Labs2.60.5-2.2 mmol/LProcalcitonin125.37<0.050 ng/ml			
$\begin{array}{ccccccc} Lactic acid & 2.6 & 0.5-2.2 \mmol/L \\ Procalcitonin & 125.37 & <0.050 \mmod ng/ml \\ High sensitivity troponin #1 & 492.4 & 0-53.5 \mmod ng/ml \\ High sensitivity troponin #2 & 585.9 & 0-53.5 \mmod ng/ml \\ Myoglobin & >900 & <10-110 \mmod ng/ml \\ Total creatine kinase & 5913 & 46-171 \mmod U/L \\ Lactate dehydrogenase & 457 & 120-246 \mmod U/L \\ Brain natriuretic peptide & 1317.6 & 0-100.0 \mmod pg/ml \\ C-reactive protein & 185.9 & 0-10 \mmod ng/L \\ International normalized ratio & 1.4 & 0.8-1.2 \\ Partial thromboplastin time & 34.3 & 25.0-37.0 \mmod sec \\ D-dimer & 1.810 & <0.500 \mmod ng/ml \\ Fibrinogen & 604 & 175-400 \mmod ng/L \\ Salicylates & <3.0 & 2.0-29.0 \mmod ng/L \\ Acetaminophen & 4 & 0-199 \mmod ng/ml \\ Ethyl alcohol & <10 & 0-10 \mmod ng/ml \\ Ethyl alcohol & <10 & 0-10 \mmod ng/ml \\ COVID-19 \mmod PCR & Presumptive \\ negative \\ \end{array}$		0.0	0.0-0.0 g/uL
$\begin{array}{c c c c c c c c c c c c c c c c c c c $			
High sensitivity troponin #1492.4 $0.53.5 \text{ ng/ml}$ High sensitivity troponin #2585.9 $0.53.5 \text{ ng/ml}$ Myoglobin>900<10-110 ng/ml			
$\begin{array}{c c c c c c c c c c c c c c c c c c c $			
$\begin{array}{llllllllllllllllllllllllllllllllllll$			
$\begin{array}{c c} \mbox{Total creatine kinase} & 5913 & 46-171 \mbox{U/L} \\ \mbox{Lactate dehydrogenase} & 457 & 120-246 \mbox{U/L} \\ \mbox{Brain natriuretic peptide} & 1317.6 & 0-100.0 \mbox{ pg/ml} \\ \mbox{C-reactive protein} & 185.9 & 0-10 \mbox{ mg/L} \\ \mbox{International normalized ratio} & 1.4 & 0.8-1.2 \\ \mbox{Partial thromboplastin time} & 34.3 & 25.0-37.0 \mbox{ sec} \\ \mbox{D-dimer} & 1.810 & <0.500 \mbox{ mg/ml} \\ \mbox{Fibrinogen} & 604 & 175-400 \mbox{ mg/dL} \\ \mbox{Salicylates} & <3.0 & 2.0-29.0 \mbox{ mg/dL} \\ \mbox{Acetaminophen} & 4 & 0-199 \mbox{ mg/ml} \\ \mbox{Ethyl alcohol} & <10 & 0-10 \mbox{ mg/dL} \\ \mbox{COVID-19 PCR} & \mbox{Presumptive} \\ \mbox{negative} & \nbox{Not Detected} \\ \mbox{pH} & 7.49 & 7.35-7.45 \mbox{ pH} \\ \mbox{pCO}_2 & 27.5 & 35.0-45.0 \\ \end{array}$		585.9	
$\begin{array}{c c} \mbox{Lactate dehydrogenase} & 457 & 120-246 \mbox{ U/L} \\ \mbox{Brain natriuretic peptide} & 1317.6 & 0-100.0 \mbox{ pg/ml} \\ \mbox{C-reactive protein} & 185.9 & 0-10 \mbox{ mg/L} \\ \mbox{International normalized ratio} & 1.4 & 0.8-1.2 \\ \mbox{Partial thromboplastin time} & 34.3 & 25.0-37.0 \mbox{ sec} \\ \mbox{D-dimer} & 1.810 & <0.500 \mbox{ mg/ml} \\ \mbox{Fibrinogen} & 604 & 175-400 \mbox{ mg/dL} \\ \mbox{Salicylates} & <3.0 & 2.0-29.0 \mbox{ mg/dL} \\ \mbox{Acetaminophen} & 4 & 0-199 \mbox{ mg/ml} \\ \mbox{Ethyl alcohol} & <10 & 0-10 \mbox{ mg/dL} \\ \mbox{COVID-19 PCR} & \mbox{Presumptive} \\ \mbox{negative} & \nbox{Not Detected} \\ \mbox{megative} \\ \end{tabular}$	Myoglobin	>900	<10-110 ng/ml
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Total creatine kinase	5913	46-171 U/L
C-reactive protein 185.9 0-10 mg/L International normalized ratio 1.4 0.8-1.2 Partial thromboplastin time 34.3 25.0-37.0 sec D-dimer 1.810 <0.500 mg/ml	Lactate dehydrogenase	457	120-246 U/L
International normalized ratio 1.4 0.8-1.2 Partial thromboplastin time 34.3 25.0-37.0 sec D-dimer 1.810 <0.500 mg/ml	Brain natriuretic peptide	1317.6	0-100.0 pg/ml
International normalized ratio 1.4 0.8-1.2 Partial thromboplastin time 34.3 25.0-37.0 sec D-dimer 1.810 <0.500 mg/ml	C-reactive protein	185.9	0-10 mg/L
D-dimer 1.810 <0.500 mg/ml Fibrinogen 604 175-400 mg/dL Salicylates <3.0	-	1.4	
D-dimer 1.810 <0.500 mg/ml Fibrinogen 604 175-400 mg/dL Salicylates <3.0	Partial thromboplastin time	34.3	25.0-37.0 sec
Fibrinogen 604 175-400 mg/dL Salicylates <3.0	•		
Salicylates<3.02.0-29.0 mg/dLAcetaminophen40-199 mg/mlEthyl alcohol<10			
Acetaminophen40-199 mg/mlEthyl alcohol<10			
Ethyl alcohol COVID-19 PCR<10 Presumptive negative0-10 mg/dL Not Detected negativeArterial Blood Gas pH pCO27.49 27.57.35-7.45 pH 35.0-45.0			
COVID-19 PCRPresumptive negativeNot DetectedArterial Blood Gas pH7.497.35-7.45 pHpCO227.535.0-45.0			0
negative Arterial Blood Gas pH 7.49 7.35-7.45 pH pCO2 27.5 35.0-45.0			
Arterial Blood Gas 7.49 7.35-7.45 pH pCO2 27.5 35.0-45.0			NUL DELECIEU
pH 7.49 7.35-7.45 pH pCO ₂ 27.5 35.0-45.0		negative	
pCO ₂ 27.5 35.0-45.0			
mm Hg	pCO ₂	27.5	35.0-45.0
			mm Hg

mL, microliters; *g*, grams; *dL*, deciliter; *K*, thousand; *mEq*, milliequivalents; *L*, liter; *mg*, milligrams; *U*, units; *mmol*, millimoles; *ng*, nanogram; *ml*, milliliters; *sec*, seconds; *COVID-19 PCR*, coronavirus disease 2019 polymerase chain reaction test; *pCO*₂, partial pressure of carbon dioxide.

Table 1. Continued.

	Laboratory	Reference
Laboratory name	value	ranges
pO ₂	75.5	80.0-100
- 2		mm Hg
HCO ₃	20.3	22.0-26.0
, , , , , , , , , , , , , , , , , , ,		mEq/L
Total CO ₂	21.1	22-32 mEq/L
Oxygen Saturation	93%	94-97%
Urinalysis		
Urine protein	4+	Negative
Urine ketones	Negative	Negative
Urine blood	3+	Negative
Urine nitrite	Positive	Negative
Urine leukocyte esterase	1+	Negative
Urine red blood cells	0-4	0-4/high
		power field
Urine white blood cells	75-100	0-2/high
		power field
Urine epithelial cells	Moderate	No Units. No
		Range.
Urine bacteria	Marked	No Units. No
		Range.
Urine glucose	Negative	Negative
Urine Drug Screen		
Amphetamines	Positive	Negative
Methamphetamines	Positive	Negative
Cannabinoids	Positive	Negative

mm Hg, millimeters of mercury; pO_2 , partial pressure of oxygen; *mm* Hg, millimeters of mercury; HCO_3 , bicarbonate; *mEq*, milliequivalents; *L*, liter.

the head, chest, abdomen, and pelvis showed no acute fractures or hemorrhage, decreasing the chance of the patient suffering from pathology such as pneumothorax, internal bleeding, or an acute cerebral vascular accident.

The patient presented in obvious respiratory distress and had oxygen saturations of only 91% on arrival, making cardiopulmonary diagnoses high on our list of differential diagnoses. Given the pitting edema, respiratory failure, and the CXR (Image 1) showing cardiomegaly, new-onset heart failure was suspected. The patient also had an elevated troponin level, but no signs of ST-segment elevation on ECG as seen in Image 2. The troponin was likely elevated due to the patient's significantly elevated blood pressure suggesting hypertensive emergency. His elevated white blood cell count, slightly elevated lactic acid level, and abnormal vital signs indicated severe sepsis likely from an infectious source with the most likely etiology an acute urinary tract infection, based on urinalysis results. Renal insufficiency was noted on laboratory evaluation as well, likely resulting from cardiac dysfunction or severe sepsis with multiorgan dysfunction.

Toxidromes or overdose were also considered. The patient had no reported or known medical history, so prescribed psychiatric medications were unlikely. Salicylate toxicity was considered given the patient's respiratory alkalosis, pulmonary



Image 1. Anterior-posterior chest radiograph of a 48-year-old male with respiratory distress and altered mental status.

edema, hyperthermia, and altered mental status. However, initial salicylate levels were negative as were acetaminophen and ethanol levels. Alcohol withdrawal was considered as well due to the patient's altered mental status and autonomic instability, but no other exam or history findings supported this. His urine drug screen was positive for methamphetamine, amphetamines, and cannabinoids. The physical exam findings were concerning for signs of IV drug use suggesting that this patient's acute illness was possibly related to polysubstance abuse. Infective endocarditis was a consideration as well based on his fever, IV drug use, and likely new congestive heart failure. However, further diagnostic studies with echocardiogram and blood culture results would be needed to include or exclude this diagnosis.

Central nervous system infection was considered as well and further testing with lumbar puncture could be performed to assess for this. Given the patient's presentation, vital signs, labs, and imaging findings, the conclusion could be made that he suffered from cardiogenic and septic shock. Sources of acute illness include urinary infection, possible endocarditis or bacteremia, and polysubstance abuse.

CLINICAL DIAGNOSIS

Cardiorenal syndrome (CRS) secondary to septic shock and tachycardia-induced cardiomyopathy.

CASE OUTCOME

In the ED, the patient was diagnosed with cardiorenal syndrome based on a combination of other diagnoses including severe sepsis secondary to urinary tract infection, congestive heart failure, non-ST segment elevation myocardial infarction (NSTEMI), hypertensive emergency, hypoxic respiratory failure, acute kidney injury, and polysubstance abuse including methamphetamine and marijuana. He was admitted to the ICU, and consulting



Image 2. Electrocardiogram of a 48-year-old male with respiratory distress and altered mental status.

specialties included neurology, cardiology, nephrology, pulmonology, and infectious disease.

The neurologist reported the patient's acute metabolic encephalopathy was multifactorial and related to methamphetamine abuse, hyperthermia, hypoxia, and sepsis. While in the ICU, the patient self-extubated after three days and was alert and oriented to person, place, and time. Evaluation by cardiology determined that the patient suffered from hypertensive emergency with non-STEMI and was started on aspirin and a heparin drip. Transesophageal echocardiogram was negative for vegetations or valvular lesions. Left ventricular ejection fraction was 15-20% with signs of combined systolic and diastolic heart failure and was attributed to methamphetamine use. The patient required vasopressor therapy with norepinephrine and vasopressin as well as dobutamine for cardiogenic shock. The cardiologist discussed potential cardiac catheterization once stabilized; however, given global hypokinesis, it was unlikely for there to be single vessel disease.

The pulmonologist and nephrologist agreed the acute respiratory failure with hypoxia was due to pulmonary edema. After chart review, the patient was found to have acute on chronic kidney disease. The cause of this injury was likely multifactorial including CRS given the clinical picture of volume overload, tachycardia-induced cardiomyopathy from methamphetamine abuse with decreased left ventricular ejection fraction, and potential acute tubular necrosis secondary to septic shock. A furosemide trial did not produce adequate urine output, so the patient was started on sustained, low-efficiency dialysis and his respiratory status improved. Nephrology supported the diagnosis of CRS and mentioned that the patient might have a mixed picture of cardiogenic and septic shock, which would be consistent with CRS, specifically type five.

The infectious disease specialist diagnosed the patient with septic shock due to bacteremia from Gram-positive cocci in chains likely secondary to IV drug use, and initiated treatment with ceftriaxone and clindamycin. Based on leukocytosis and increasing procalcitonin, IV immunoglobulin was added for possible toxic shock syndrome secondary to

Table 2. Classification of cardiorenal syndrome based on a	
system proposed by Ronco and McCullough. ²	

system proposed by Ronoo an		
Cardiorenal Syndrome Type	Characteristics	
Type 1 (acute cardiorenal)	Acute cardiac impairment leading to acute kidney injury	
Type 2 (chronic cardiorenal)	Chronic cardiac impairment leading to renal impairment	
Type 3 (acute renocardiac)	Acute kidney injury leading to cardiac impairment	
Type 4 (chronic renocardiac)	Chronic kidney disease leading to cardiac impairment	
Type 5 (secondary cardiorenal)	Systemic condition leading to both cardiac and renal impairment	

group A streptococcal bacteremia. The patient responded positively to the above treatments. On repeat blood cultures, he was positive for *Enterococcus faecalis*. In addition, he had an elevated rapid plasma reagin titer consistent with late, latent syphilis. The patient ultimately left the hospital against medical advice despite extensive discussion regarding his multiple diagnoses requiring further management and care.

RESIDENT DISCUSSION

Cardiorenal syndrome encompasses a spectrum of disorders involving both the heart and kidneys in which acute or chronic dysfunction in one organ may induce acute or chronic dysfunction in the other organ.¹ Cardiorenal syndrome is divided into two major groups, cardiorenal and renocardiac syndromes, and five subgroups based on which organ is the cause of damage to the other organ.² These hemodynamic interactions of the heart and kidney are affected by heart failure and atherosclerotic disease in both organ systems. They are also affected by chronic kidney disease (CKD) and the alterations it causes in the neurohormonal activation, cytokines, and the biochemical perturbations across the anemia–inflammation–bone mineral axis.¹ Structural changes in the heart unique to kidney disease progression also play a role in the development of CRS.¹

As summarized in Table 2, there are five types of CRS:² CRS type 1 is characterized by acute worsening of cardiac function leading to an acute kidney injury (AKI);³ CRS type 2 is characterized by chronic cardiac dysfunction leading to renal dysfunction and can be used to describe chronic heart failure leading to renal failure;³ CRS type 3 is characterized by acute cardiac dysfunction as a result of acute renal impairment;³ CRS type 4 describes CKD leading to cardiac dysfunction (left ventricular failure or diastolic heart failure);³ and CRS type 5 is characterized by simultaneous cardiac and renal dysfunction as a part of a systemic condition whether it be acute or chronic. This most commonly includes systemic conditions such as sepsis and less so other conditions such as amyloid or vasculitis.³

In the acute setting, severe sepsis represents the most common and serious condition, which can affect both

organs.⁴ It can induce AKI while leading to profound myocardial depression.⁴ The onset of myocardial functional depression and a state of inadequate cardiac output can further decrease renal function as discussed in type 1 CRS, and the development of AKI can affect cardiac function as described in type 3 CRS.¹ Renal ischemia may then induce further myocardial injury in a vicious cycle injurious to both organs.¹

To diagnose CRS, tools include biomarkers such as brain natriuretic peptide, echocardiography, and renal ultrasound. In addition, measuring central venous pressure, systolic pulmonary artery pressure, pulmonary capillary wedge pressure and left atrial pressure, and cardiac output will help in determining degree of congestion.¹ Renal ultrasonography helps identify renal venous congestion and its clinical significance in CRS.¹

Diuretics are key in treating CRS.¹ However, the kidneys can stop responding due to the "braking phenomenon."1 For cardiogenic shock and severe hypotensive episodes in patients with CRS, which can cause oliguria or anuria, inotropes are frequently used to improve cardiac output and renal blood flow.5 Historically, low-dose dopamine has been used to increase renal blood flow although there is conflicting evidence regarding its effect upon glomerular filtration rate.5 No clinical trial to date has demonstrated a benefit with regard to lower mortality rates.⁵ Trials of dobutamine and milrinone have shown improvement of cardiac index and, in proportion, renal blood flow; however, this has not translated into survival benefit.5 Treatment is directed at the prompt identification, eradication, and treatment of the source of infection while supporting organ function with invasively guided fluid resuscitation in addition to inotropic and vasopressor drug support.6

FINAL DIAGNOSIS

Cardiorenal syndrome type 5.

KEY TEACHING POINTS

- Cardiorenal syndrome is considered dysfunction in the heart or kidneys that worsens the function of the other organ. It has multiple contributing factors such as neurohormonal system activation leading to reduced forward flow and renal perfusion and increased venous pressure.³
- CRS is classified into two major groups, cardiorenal and renocardiac, and five subgroups based on which organ is the cause of damage to the other organ.
- To diagnose CRS, tools include biomarkers such as brain natriuretic peptide, echocardiography,

and renal ultrasound as well as measuring central venous pressure, systolic pulmonary artery pressure, pulmonary capillary wedge pressure and left atrial pressure, and cardiac output.

• Early diagnosis is important, and medical treatment options are focused on improving cardiac function, reducing volume overload, and managing heart failure and chronic kidney disease.³

The authors attest that their institution requires neither Institutional Review Board approval, nor patient consent for publication of this case report. Documentation on file.

Address for Correspondence: Justin E. Pile, DO, MS, Swedish Hospital Part of Northshore, Department of Emergency Medicine, 5140 North California Avenue, Chicago, IL60625. Email: jpile@schosp.org.

Conflicts of Interest: By the *CPC-EM* article submission agreement, all authors are required to disclose all affiliations, funding sources and financial or management relationships that could be perceived as potential sources of bias. The authors disclosed none.

Copyright: © 2021 Pile et al. This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (<u>CC BY 4.0</u>) License. See: <u>http://creativecommons.org/licenses/by/4.0/</u>

REFERENCES

- Rangaswami J, Bhalla J, Chang T, et al. Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: a scientific statement from the American Heart Association. *Circulation*. 2019;139(16):e840-78.
- Ronco C, McCullough P, Anker S, et al. Cardio-renal syndromes: report from the Consensus Conference of the Acute Dialysis Quality Initiative. *Eur Heart J.* 2010;31(6):703-11.
- 3. Hadjiphilippou S and Kon S. Cardiorenal syndrome: review of our current understanding. *J R Soc Med.* 2016;109(1):12-7.
- Ronco C and Di Lullo L. Cardiorenal syndrome. *Heart Fail Clin*. 2014;10(2):251-80.
- Shah BN and Greaves K. The cardiorenal syndrome: a review. Int J Nephrol. 2010;2011:920195.
- Ronco C, Haapio M, House A, et al. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52(19):1527-39.